Panik Bozukluğun Psikofarmakolojisi
Özet
Panik bozukluğu (PB), tekrarlayan ve öngörülemeyen panik ataklarla seyreden, gelecekteki ataklara karşı beklenti anksiyetesi ve agorafobi gibi davranış değişikliklerine yol açan kronik bir anksiyete bozukluğudur. Hastalığın kesin patogenezi belirsizliğini korurken, en yaygın ve etkili tedavi yaklaşımlarını farmakoterapi ile bilişsel davranışçı terapiler oluşturmaktadır. Farmakolojik alanda Serotonin Gerialım İnhibitörleri (SSRI), Serotonin Norepinefrin Gerialım İnhibitörleri (SNRI), Trisiklik Antidepresanlar (TSA) ve Benzodiazepinler (BDZ) gibi çeşitli ilaç sınıfları etkin şekilde kullanılmaktadır. Olumlu yan etki profilleri nedeniyle uluslararası kılavuzlarda SSRI'lar birinci basamak tedavi olarak önerilirken, yüksek toksisite riskine sahip TSA'lar ve bağımlılık potansiyeli taşıyan benzodiazepinler ise daha gerideki basamaklarda ya da kısa süreli akut dönem müdahalelerinde tercih edilmektedir. İlaçların birden kesilmesi nüks ve kesilme belirtilerine yol açabileceğinden, tedavinin en az 12 ay sürdürülmesi ve dozun yavaşça azaltılması önerilmektedir. Sonuç olarak panik bozukluğu, tedavisi kesildiğinde yineleme eğilimi yüksek, yaşam boyu sürebilen bir yapıya sahip olduğundan sıklıkla psikolojik ve farmakolojik müdahalelerin kombinasyonunu gerektirmektedir.
Panic disorder (PD) is a chronic anxiety disorder characterized by recurrent and unpredictable panic attacks, leading to anticipatory anxiety and behavioral changes such as agoraphobia. While its definitive pathogenesis remains unclear, the most common and effective treatment approaches consist of pharmacotherapy and cognitive behavioral therapies. In the pharmacological field, various drug classes including Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), and Benzodiazepines (BDZs) are effectively utilized. Due to their favorable side effect profiles, international guidelines recommend SSRIs as first-line treatment, whereas TCAs with high toxicity risks and benzodiazepines with addiction potential are preferred in later lines or for short-term acute interventions. Since abrupt discontinuation of medications can lead to relapse and withdrawal symptoms, it is recommended to maintain the treatment for at least 12 months and taper the dose gradually. Consequently, panic disorder possesses a lifelong nature with a high tendency to recur when treatment is discontinued, thereby frequently requiring a combination of psychological and pharmacological interventions.
Referanslar
Köroğlu E. American Psychiatric Association. Diagnostic and StatisticalManual of Mental Disorders fifth edition (DSM–V). Ankara: Hekimler Yayın Biliği, 2014: Washington DC: AmericanPsychiatric Association, ;
Roy-Byrne P, Craske M, Lancet MS-T, 2006 undefined. Panic disorder. Elsevier [Internet]. [cited 2022 Sep 4]; Available from: https://www.sciencedirect.com/science/article/pii/S014067360669418X
July 2006, Vol 51, Supplement 2: CLINICAL PRACTICE GUIDELINES: Management of Anxiety Disorders - ProQuest [Internet]. [cited 2022 Sep 4]. Available from: https://www.proquest.com/openview/e446c42f42ed8f899f6522dd934842d0/1?pq-origsite=gscholar&cbl=35547
Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia. 1964 Nov;5(6):397–408.
Dresler T, Guhn A, Tupak S V., Ehlis AC, Herrmann MJ, Fallgatter AJ, et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm. 2013 Jan;120(1):3–29.
Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017 Apr 3;18(3):162–214.
American Psychitatric Association Practice Guideline for the treatment of patients with panic disorder. Second Edition. http:// www.psychiatry.org/psychiatrists/practice/cilinical-guidelines,2010.
Perna G, Schruers K, Alciati A, Caldirola D. Novel investigational therapeutics for panic disorder. Expert Opin Investig Drugs. 2015 Apr 1;24(4):491–505.
Freire RC, Zugliani MM, Garcia RF, Nardi AE. Treatment-resistant panic disorder: A systematic review. Expert Opin Pharmacother. 2016 Jan 22;17(2):159–68.
Perna G, Guerriero G, emerging DC-E opinion on, 2011 undefined. Emerging drugs for panic disorder. Taylor Fr [Internet]. 2011 Dec [cited 2022 Sep 5];16(4):631–45. Available from: https://www.tandfonline.com/doi/abs/10.1517/14728214.2011.628313
Nay W, Brown R, Research RR-N-P, 2013 undefined. Longitudinal course of panic disorder with and without agoraphobia using the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Elsevier [Internet]. [cited 2022 Sep 5]; Available from: https://www.sciencedirect.com/science/article/pii/S0165178113001376
Heldt E, Kipper L, Blaya C, … GS-BJ of, 2011 undefined. Predictors of relapse in the second follow-up year post cognitive-behavior therapy for panic disorder. SciELO Bras [Internet]. [cited 2022 Sep 5]; Available from: https://www.scielo.br/j/rbp/a/pMbsqyvBxWmbGhK7VXVq8tj/abstract/?lang=en
Israel Pérez Benítez C, Shea ÃMT, Raffa S, Rende R, Dyck IR, Ramsawh HJ, et al. Anxiety sensitivity as a predictor of the clinical course of panic disorder: a 1‐year follow‐up study. Wiley Online Libr [Internet]. 2009 Apr [cited 2022 Sep 5];26(4):335–42. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/da.20423
Ansell EB, Pinto A, Edelen MO, Markowitz JC, Sanislow CA, Yen S, et al. The association of personality disorders with the prospective 7-year course of anxiety disorders. cambridge.org [Internet]. [cited 2022 Sep 5]; Available from: https://www.cambridge.org/core/journals/psychological-medicine/article/association-of-personality-disorders-with-the-prospective-7year-course-of-anxiety-disorders/AA243C45B4AB91CDF70865F8DC456F06
Gundlach A, Knight KD. Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Summary Recommendation Created by.
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(SUPPL. 1):1–21.
Drugs for the treatment of depression labbate - Google Akademik [Internet]. [cited 2022 Sep 5]. Available from: https://scholar.google.com/scholar?hl=tr&as_sdt=0%2C5&q=Drugs+for+the+treatment+of+depression+labbate&btnG=
Donovan M, Glue P, Kolluri S, disorders BE-J of affective, 2010 undefined. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders—a meta-analysis. Elsevier [Internet]. [cited 2022 Sep 5]; Available from: https://www.sciencedirect.com/science/article/pii/S0165032709002821
Mavissakalian M, Clinical JP-J of, 2002 undefined. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. journals.lww.com [Internet]. [cited 2022 Sep 5]; Available from: https://journals.lww.com/psychopharmacology/Fulltext/2002/06000/Duration_of_Imipramine_Therapy_and_Relapse_in.00010.aspx
Perna G, Alciati A, Riva A, Micieli W, Caldirola D. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep. 2016 Mar 1;18(3):1–16.
Thanacoody HKR, Thomas SHL. Tricyclic antidepressant poisoning: Cardiovascular toxicity. Toxicol Rev. 2005;24(3):205–14.
Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant Discontinuation Syndrome: Consensus Panel Recommendations for Clinical Management and Additional Research. J Clin Psychiatry [Internet]. 2006 [cited 2022 Sep 5];67(4). Available from: http://www.ncbi.nlm.
Dipl-Psych Borwin Bandelow med, Zohar J, Hollander E, Kasper S, Möller H-J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic. Taylor Fr [Internet]. 2008 [cited 2022 Sep 5];9(4):248–312. Available from: https://www.tandfonline.com/doi/abs/10.1080/15622970802465807
Blanco C, Bragdon L, … FS-IJ, 2013 undefined. The evidence-based pharmacotherapy of social anxiety disorder. academic.oup.com [Internet]. [cited 2022 Sep 5]; Available from: https://academic.oup.com/ijnp/article-abstract/16/1/235/629354
Ross DC, Klein DF, Uhlenhuth EH. Improved statistical analysis of moclobemide dose effects on panic disorder treatment. Eur Arch Psychiatry Clin Neurosci. 2010 Apr;260(3):243–8.
Nardi A, Valença A, Nascimento I, … FL-P, 2005 undefined. A three-year follow-up study of patients with the respiratory subtype of panic disorder after treatment with clonazepam. Elsevier [Internet]. [cited 2022 Sep 5]; Available from: https://www.sciencedirect.com/science/article/pii/S0165178105002015
Clonazepam in the Treatment of Panic Disorder With or Withou... : Journal of Clinical Psychopharmacology [Internet]. [cited 2022 Sep 5]. Available from: https://journals.lww.com/psychopharmacology/Fulltext/1997/10000/Clonazepam_in_the_Treatment_of_Panic_Disorder_With.8.aspx
Psychiatry GC-J of C, 2004 undefined. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. psychiatrist.com [Internet]. [cited 2022 Sep 5]; Available from: https://www.psychiatrist.com/read-pdf/29678/
Baldwin D, Anderson I, … DN-J of, 2014 undefined. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines. journals.sagepub.com [Internet]. 2014 [cited 2022 Sep 5];28(5):403–39. Available from: https://journals.sagepub.com/doi/abs/10.1177/0269881114525674
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014 Jul 2;14(SUPPL.1).
Freire R, Amrein R, … MM-J of C, 2017 undefined. A 6-year posttreatment follow-up of panic disorder patients: treatment with clonazepam predicts lower recurrence than treatment with paroxetine. journals.lww.com [Internet]. [cited 2022 Sep 5]; Available from: https://journals.lww.com/psychopharmacology/FullText/2017/08000/A_6_Year_Posttreatment_Follow_up_of_Panic_Disorder.8.aspx
Bighelli I, Trespidi C, Castellazzi M, Cipriani A, Furukawa TA, Girlanda F, et al. Antidepressants and benzodiazepines for panic disorder in adults. Cochrane Database Syst Rev. 2016 Sep 12;2016(9).
Moylan S, Staples J, Ward S, … JR-J of clinical, 2011 undefined. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. journals.lww.com [Internet]. [cited 2022 Sep 5]; Available from: https://journals.lww.com/psychopharmacology/fulltext/2011/10000/the_efficacy_and_safety_of_alprazolam_versus_other.17.aspx
de Psicofarmacologia S, Ribeiro L, Busnello J, Kauer-Sant M, Madruga M, Quevedo J, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. SciELO Bras [Internet]. [cited 2022 Sep 5];34(10):2001. Available from: https://www.scielo.br/j/bjmbr/a/hS8TrZhWL6Ht6HV99dtZrsw/abstract/?lang=en
Canadian Psychiatric Association. Clinical practice guidelines, Management of anxiety disorders. Can J Psychiatry, Vol 51, Suppl 1, July 2006
Bakker A, Van Balkom AJLM, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: A meta-analysis. Acta Psychiatr Scand. 2002;106(3):163–7.
July 2006, Vol 51, Supplement 2: CLINICAL PRACTICE GUIDELINES: Management of Anxiety Disorders - ProQuest [Internet]. [cited 2022 Sep 5]. Available from: https://www.proquest.com/openview/e446c42f42ed8f899f6522dd934842d0/1?cbl=35547&pq-origsite=gscholar&parentSessionId=TB932gpuD%2FdiIaHQ1lVL3QTeoCN0%2FWKOf8CbSWHQWqI%3D
Furukawa TA, Katherine M, Barlow DH, Gorman JM, Woods SW, Money R, et al. Evidence‐based guidelines for interpretation of the Panic Disorder Severity Scale. Wiley Online Libr [Internet]. 2009 Oct [cited 2022 Sep 4];26(10):922–9. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/da.20532
Generalised Anxiety Disorder in Adults: Management in Primary, Secondary and Community Care - PubMed [Internet]. [cited 2022 Sep 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/22536620/
